“`html
Real-world Evidence Study Shows Positive Experiences with Eptinezumab for Chronic Migraine
Background
Despite advances in migraine treatment, many patients still face significant burden due to exclusion from traditional trials. This study aimed to understand patients’ and physicians’ real-world experiences with eptinezumab for chronic migraine.
Methods
- Observational, multi-site (n = 4), US-based study
- Patients ≥ 18 years with chronic migraine
- Retrospective chart review, patient survey, and physician interview
Key Findings
- 94 patients enrolled, with 83% female and mean age of 49.2 years
- Patients reported increase from 8 to 18 “good” days/month after eptinezumab treatment
- Use of prescription and over-the-counter medication dropped significantly post-treatment
- Concerns about infusions decreased from 62% to 14% after eptinezumab infusion
Conclusion
This real-world evidence study demonstrated high overall satisfaction with the effectiveness of eptinezumab treatment for chronic migraine among most patients and their physicians.
“`
